JHJiangqian Huang

Jiangqian Huang

*This is an algorithmically generated author record based on publicly available information.

Jiangqian Huang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exosome-like nanoparticles derived from Sarcandra glabra regulate the Wnt pathway to intervene in the progression of gastric cancer

    by Zihan Gao, Jiangqian Huang, Wenhui Yang, Yuning Gu, Zhaofeng Liang, Xulin Zhou

    Gastric cancer remains a leading global malignancy, necessitating the development of novel therapeutic approaches. Plant-derived exosome-like nanoparticles have emerged as promising therapeutic vehicles due to their high biocompatibility and low immunogenicity; however, the potential anti-gastric cancer effects of Sarcandra glabra-derived exosome-like nanoparticles (SELNs) have not been previously investigated. Given the central role of Wnt/β-catenin signaling in driving gastric cancer progression, we investigated whether SELNs exert antitumor effects by modulating this axis. SELNs were isolated via differential ultracentrifugation, and their efficacy and underlying mechanisms were evaluated using a combination of in vitro functional assays and in vivo xenograft models. We found that SELNs significantly inhibited gastric cancer cell proliferation, migration, invasion, and epithelial-mesenchymal transition, while promoting apoptosis. In vivo administration of SELNs effectively suppressed tumor growth. Mechanistically, SELNs impaired the protein stability and nuclear translocation of β-catenin, which subsequently downregulated its downstream targets, c-Myc and Cyclin D1. Furthermore, SELNs sensitized gastric cancer cells to cisplatin, demonstrating a synergistic suppression of Wnt pathway activity. In conclusion, this study revealed that SELNs exert multifaceted anti-gastric cancer effects by targeting the Wnt/β-catenin pathway and can sensitize cancer cells to chemotherapy, providing a novel natural nanotherapeutic strategy for gastric cancer treatment.